Nuclein
Austin, US · Founded 2017 · Texas LLC
Nuclein makes the DASH Rapid PCR System, a compact point-of-care diagnostic instrument that delivers lab-quality PCR test results in about 15 minutes from a single cartridge. It is used in clinics such as urgent care, pediatric, and primary care settings to test for multiple viruses during a patient visit.
Founders & leadership
Nuclein was founded in 2017 by Alan Blake.
AB
Alan BlakeinFounder
Board
RC
Richard CrockettBoard director
WN
Walter NarajowskiBoard director
SC
Sanjay ChandraBoard director
JB
John ButlerBoard director
WC
William CunninghamBoard director
HD
H. David ShockleyBoard director
Reported raises · per SEC filings
Form D private placements$46.9M disclosed across 5 of 9 rounds · 2019–2026
▶$9.3MraisedAug 2026 · 15 investors · BiotechnologyRule 506(b)
▶$9.3MraisedAug 2026 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alan BlakeExecutive Officer, Director
- Richard CrockettDirector
- William CunninghamDirector
- Douglas BryantDirector
- Sanjay ChandraDirector
- H. David ShockleyDirector
- Walter NarajowskiDirector
- Jeffrey StukulsExecutive Officer
- Offering amount
- $16.1M
- Amount sold
- $9.3M
- First sale
- Jun 2026
- Incorporated
- Limited Liability Company, Texas
- Federal exemptions
- 06b
▶$19.1MraisedApr 2026 · 49 investors · BiotechnologyRule 506(b)
▶$19.1MraisedApr 2026 · 49 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Douglas BryantDirector
- H. David ShockleyDirector
- Alan BlakeExecutive Officer, Director
- Walter NarajowskiDirector
- William CunninghamDirector
- Richard CrockettDirector
- Sanjay ChandraDirector
- Jeffrey StukulsExecutive Officer
- Offering amount
- $25M
- Amount sold
- $19.1M
- Sales commissions
- $1M
- Placement agents
- Sanjay Chandra
- First sale
- Jul 2025
- Incorporated
- Limited Liability Company, Texas
- Federal exemptions
- 06b
▶$9.4MraisedFeb 2026 · 34 investors · BiotechnologyRule 506(b)
▶$9.4MraisedFeb 2026 · 34 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alan BlakeExecutive Officer, Director
- Sanjay ChandraDirector
- William CunninghamDirector
- Richard CrockettDirector
- Douglas BryantDirector
- Walter NarajowskiDirector
- Jeffrey StukulsExecutive Officer
- H. David ShockleyDirector
- Offering amount
- $15M
- Amount sold
- $9.4M
- Sales commissions
- $1.5M
- Placement agents
- Sanjay Chandra
- First sale
- Jan 2025
- Incorporated
- Limited Liability Company, Texas
- Federal exemptions
- 06b
▶$8.8MraisedAug 2024 · 18 investors · BiotechnologyRule 506(b)
▶$8.8MraisedAug 2024 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alan BlakeExecutive Officer, Director
- William CunninghamDirector
- H. David ShockleyDirector
- Richard CrockettDirector
- Walter NarajowskiDirector
- Sanjay ChandraDirector
- John ButlerDirector
- Offering amount
- $15M
- Amount sold
- $8.8M
- First sale
- Dec 2023
- Incorporated
- Limited Liability Company, Texas
- Federal exemptions
- 06b
▶Undisclosed amountofferedMar 2023 · BiotechnologyRule 506(b)
▶Undisclosed amountofferedMar 2023 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sanjay ChandraDirector
- Richard CrockettExecutive Officer, Director
- Jeffrey StukulsExecutive Officer
- John ButlerDirector
- David ShockleyDirector
- William CunninghamDirector
- Alan BlakeExecutive Officer, Director
- Incorporated
- Limited Liability Company, Texas
- Federal exemptions
- 06b
▶Undisclosed amountofferedJul 2022 · BiotechnologyRule 506(b)
▶Undisclosed amountofferedJul 2022 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John ButlerDirector
- Richard CrockettExecutive Officer, Director
- Alan BlakeExecutive Officer, Director
- David ShockleyDirector
- Sanjay ChandraDirector
- William CunninghamDirector
- Incorporated
- Limited Liability Company, Texas, 2017
- Federal exemptions
- 06b
▶Undisclosed amountofferedJan 2021 · BiotechnologyRule 506(b)
▶Undisclosed amountofferedJan 2021 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alan BlakeExecutive Officer, Director
- Sanjay ChandraDirector
- John ButlerDirector
- William CunninghamDirector
- Richard CrockettExecutive Officer, Director
- Incorporated
- Limited Liability Company, Texas, 2017
- Federal exemptions
- 06b
▶$1MofferedFeb 2020 · BiotechnologyRule 506(b)
▶$1MofferedFeb 2020 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alan BlakeExecutive Officer, Director
- Richard CrockettExecutive Officer, Director
- Offering amount
- $1M
- Minimum investment
- $25K
- Proceeds to insiders
- $50K
- Incorporated
- Limited Liability Company, Texas, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with Nuclein for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Nuclein has filed a notice of an exempt offering of securities to raise $11,114,842.00 in New Funding. - intelligence360intelligence360.news · Jul 2026Frequently asked questions
- What does Nuclein do?
- Nuclein makes the DASH Rapid PCR System, a compact point-of-care diagnostic instrument that delivers lab-quality PCR test results in about 15 minutes from a single cartridge. It is used in clinics such as urgent care, pediatric, and primary care settings to test for multiple viruses during a patient visit.
- Who founded Nuclein?
- Nuclein was founded by Alan Blake in 2017.
- How much funding has Nuclein raised?
- Nuclein has disclosed $46.9M raised across 5 of its 9 known rounds.
- Where is Nuclein headquartered?
- Nuclein is headquartered in Austin, US.